Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

Robertson Foundation commits $10.2M for Duke Medicine's cell therapy research

A $10.2 million commitment from the Robertson Foundation to create a state-of-the-art Translational Cell Therapy Center (TCTC) will advance Duke Medicine's pioneering cell therapy research and treatment programs for children and adults with cancer, cerebral palsy, stroke and brain injuries suffered at birth.

19 Mar 2010

Menicon acquires all shares of Tomey from Tomey Shoji

Menicon Co., Ltd. announced on March 17 that it had acquired all shares of Tomey Co., Ltd. from Tomey Shoji Inc. The deal was completed on February 1, 2010.

19 Mar 2010

W. R. Grace earns GMP certification

W. R. Grace & Co.has earned Good Manufacturing Practices certification of its facility in Baltimore, Maryland. The certification encompasses Grace’s Quality Management System that includes the standards, procedures and manufacturing operations used by the company in the production of pharmaceutical grade silica (commonly marketed by Grace under the SYLOID® brand name).

19 Mar 2010

Atrium Innovations acquires the assets of Trophic Canada for total cash consideration of $11M

Atrium Innovations Inc., a recognized leading developer, manufacturer and marketer of professionally endorsed, science-based products for the health and nutrition industry, today announced the purchase of the assets of Trophic Canada, a leading manufacturer and distributor of vitamins, minerals and herbal supplements in the Canadian Health Food Store market.

18 Mar 2010

Varian Medical Systems to showcase radiotherapy and radiosurgery solutions at medical events in Asia

Varian Medical Systems, Inc., the world's leading manufacturer of medical technology for treating cancer with radiotherapy and radiosurgery, will showcase its technology at two medical events in Asia during the month of March:

18 Mar 2010

American Scientific Resources receives additional Bayer Healthcare order for Disintegrator Needle Destruction Device

American Scientific Resources, Inc., confirms today that it has received formal confirmation and payment advice for the additional purchase of its Disintegrator Needle Destruction Device from Bayer-Schering Pharmaceuticals.

18 Mar 2010

Bavarian Nordic completes last step to support use of IMVAMUNE, receives FDA notification

Bavarian Nordic A/S announced today that it has received notification that the U.S. Food and Drug Administration (FDA) has accepted all the actions taken by the company to address the observations made during the inspection of the manufacturing facilities in 2009. This was the last step along with the clinical and preclinical data that will be used to potentially support the use of IMVAMUNE® following a declared emergency.

18 Mar 2010

Genes allowing opium poppy to make codeine and morphine discovered

Researchers at the University of Calgary have discovered the unique genes that allow the opium poppy to make codeine and morphine, thus opening doors to alternate methods of producing these effective painkillers either by manufacturing them in a lab or controlling the production of these compounds in the plant.

18 Mar 2010

OriGene Technologies to build TrueMAB monoclonal antibody collection with $16M Series B financing funds

OriGene Technologies, Inc., a leading gene-centric life sciences company, announced the completion of a $16 million Series B financing led by IDG-Accel, SBI & TH Venture Capital Enterprise, and Zero2IPO. OriGene's previous investors Morningside Venture Investments and President International Development Corp. (PIDC) also participated in this round. The proceeds from the funding will be used to continue to build OriGene's TrueMAB™ monoclonal antibody collection.

18 Mar 2010

Enzo Biochem announces supply and distribution agreement between Enzo Life Sciences and Cancer Genetics

Enzo Biochem, Inc., a vertically integrated biotechnology company engaged in the research, development, manufacture, licensing and marketing of innovative health care products, platforms and services based on molecular and cellular technologies, announced today a supply and distribution agreement between Enzo Life Sciences and privately-owned Cancer Genetics Inc., a leading producer of nucleic acid products used in genomic research.

18 Mar 2010

CytoDyn commences full humanization of Cytolin immune therapy for treating HIV/AIDS

CytoDyn, Inc. has begun full humanization of Cytolin®, the Company’s unique immune therapy for treating HIV/AIDS. Although a murine (mouse) version of Cytolin® was used for previous human experience that included some 200 patients successfully treated for up to two years, as well as an encouraging Phase I(b)/II(a) study, the Company believes that a fully-humanized version is necessary for the clinical trial that is expected to follow the current one (described at http://clinicaltrials.gov) for the reasons explained below.

17 Mar 2010

Coastal Contacts' sales up 15% for first fiscal quarter 2010

Coastal Contacts Inc. today announced its financial results for the three months ended January 31, 2010.

17 Mar 2010

Meridian Bioscience revises fiscal 2010 guidance, expects net sales between $145M and $153M

Meridian Bioscience, Inc., Cincinnati, Ohio today announced that it is revising downward its previous sales and earnings guidance for the fiscal year ending September 30, 2010. This action is being taken as a result of weaker than expected operating results for the second quarter ending March 31, 2010, based on preliminary results to date. Separately, Meridian announced that it will file a 510(k) for FDA marketing clearance next week in connection with its illumigene™ C. difficile product.

17 Mar 2010

TSO3 reports net loss of $9.2M for fiscal 2009

TSO3 Inc. an innovator in sterilization technology for medical devices in healthcare settings using ozone, posted sales totalling $1.3 million for the fiscal year ended December 31, 2009, compared to $2.2 million one year earlier. During the year, the Company sold five of its first generation STERIZONE(R) sterilizers and accessories, whereas it sold 13 in the preceding fiscal year.

17 Mar 2010

Agilent Technologies introduces new ion exchange and size exclusion columns for analysis of bio-molecules

Agilent Technologies Inc. today announced the availability of new ion exchange and size exclusion columns specifically designed for the analysis of bio-molecules including monoclonal antibodies, recombinant proteins, peptides, vaccine products and DNA/RNA. The columns provide robust, reproducible and high-resolution solutions for biopharmaceutical manufacturers to effectively monitor the safety, efficacy and stability of their products.

17 Mar 2010

Avid Bioservices highlights data of single-use bioreactors and traditional stainless steel bioreactors

Avid Bioservices, Inc. today presented data highlighting the comparability of production run performance between the company's single-use bioreactors (Thermo Scientific HyClone S.U.B.) and its traditional stainless steel bioreactors at the Thermo Scientific BioProduction Optimization Workshop in San Francisco, California.

From Thermo Fisher Scientific Inc. 17 Mar 2010

Pew Prescription Project statement: Protect Americans from unsafe drugs made overseas

Two years after dozens of Americans lost their lives to contaminated heparin, we are still not able to protect U.S. consumers from many of the risks of pharmaceuticals manufactured in foreign factories. It is time for Congress to take action to better protect health.

17 Mar 2010

Glenmark Generics, Konec ordered to stop marketing unapproved nitroglycerin tablets

The U.S. Food and Drug Administration today ordered Glenmark Generics of Mahwah, N.J., and Konec Inc. of Tucson, Ariz., to stop marketing unapproved nitroglycerin tablets. The tablets are placed under the tongue to relieve chest pain or to stop a heart attack and are marketed in 0.3 mg, 0.4 mg, and 0.6 mg dosages.

17 Mar 2010

Human Genome Sciences to deploy Aegis Analytical's Discoverant manufacturing intelligence solution

Aegis Analytical Corp., the leading provider of Enterprise Manufacturing Intelligence software, announced today that Human Genome Sciences, Inc. will deploy Aegis’ Discoverant® as its data management, analytics and reporting solution in the scale-up and production of BENLYSTA™ (belimumab), an investigational drug for the treatment of systemic lupus that has successfully completed Phase 3 trials.

17 Mar 2010

Unapproved nitroglycerin tablets: FDA orders Glenmark Generics and Konec to stop marketing

17 Mar 2010

Manufacturing News and Research

Further Reading

Robertson Foundation commits $10.2M for Duke Medicine's cell therapy research

Menicon acquires all shares of Tomey from Tomey Shoji

W. R. Grace earns GMP certification

Atrium Innovations acquires the assets of Trophic Canada for total cash consideration of $11M

Varian Medical Systems to showcase radiotherapy and radiosurgery solutions at medical events in Asia

American Scientific Resources receives additional Bayer Healthcare order for Disintegrator Needle Destruction Device

Bavarian Nordic completes last step to support use of IMVAMUNE, receives FDA notification

Genes allowing opium poppy to make codeine and morphine discovered

OriGene Technologies to build TrueMAB monoclonal antibody collection with $16M Series B financing funds

Enzo Biochem announces supply and distribution agreement between Enzo Life Sciences and Cancer Genetics

CytoDyn commences full humanization of Cytolin immune therapy for treating HIV/AIDS

Coastal Contacts' sales up 15% for first fiscal quarter 2010

Meridian Bioscience revises fiscal 2010 guidance, expects net sales between $145M and $153M

TSO3 reports net loss of $9.2M for fiscal 2009

Agilent Technologies introduces new ion exchange and size exclusion columns for analysis of bio-molecules

Avid Bioservices highlights data of single-use bioreactors and traditional stainless steel bioreactors

Pew Prescription Project statement: Protect Americans from unsafe drugs made overseas

Glenmark Generics, Konec ordered to stop marketing unapproved nitroglycerin tablets

Human Genome Sciences to deploy Aegis Analytical's Discoverant manufacturing intelligence solution

Unapproved nitroglycerin tablets: FDA orders Glenmark Generics and Konec to stop marketing

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News